Cardiovascular complications associated with novel agents in the chronic lymphocytic leukemia armamentarium: A pharmacovigilance analysis
| Autor: | Paari Dominic, Aakash Sheth, Sahith Reddy Thotamgari, Kavitha Beedupalli, Javaria Ahmad, Shiva Jashwanth Gaddam, Udhayvir Singh Grewal |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Heart Diseases business.industry Venetoclax Antineoplastic Agents medicine.disease Leukemia Lymphocytic Chronic B-Cell Article Pharmacovigilance chemistry.chemical_compound Adverse Event Reporting System Pyrimidines chemistry Ibrutinib Internal medicine Heart failure Humans Pyrazoles Medicine Acalabrutinib Cardiology and Cardiovascular Medicine business Idelalisib Adverse effect |
| Zdroj: | Int J Cardiol |
| ISSN: | 0167-5273 |
| Popis: | Introduction Over the last few years, improved outcomes in patients with chronic lymphocytic leukemia (CLL) have been credited to the introduction of novel agents for its treatment. However, the overall cardiovascular safety profile of these agents has not been studied adequately. Methods We searched the Food and Drug Administration Adverse Event Reporting System (FAERS) database for adverse events reported for several of these novel agents: ibrutinib, acalabrutinib, venetoclax, and idelalisib. Results A total of 6074 cardiac adverse events were identified; ibrutinib (4832/36581; 13.2%) was found to have the highest risk of cardiac adverse events. The frequency of atrial fibrillation was highest (41.5%) in the ibrutinib group, while the idelalisib and acalabrutinib groups had the highest reported frequencies of heart failure (25.1%) and myocardial infarction (13.6%), respectively. Hypertension was noted to be relatively higher in the acalabrutinib (25.6%) and venetoclax (11.8%) groups. Overall reported mortality associated with cardiac events was highest in the venetoclax (29.4%) and idelalisib (27.1%) groups. Conclusion Novel agents in the CLL armamentarium have been associated with several cardiovascular adverse events. Further studies are needed to identify high-risk groups that would benefit from robust cardiovascular surveillance after initiation of treatment with these novel agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect